Bibliographic Details
| Title: |
Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. |
| Authors: |
Mugarza, Edurne1, van Maldegem, Febe1, Boumelha, Jesse1, Moore, Christopher1, Rana, Sareena1, Sopena, Miriam Llorian2, East, Philip2, Ambler, Rachel1, Anastasiou, Panayiotis1, Romero-Clavijo, Pablo1, Valand, Karishma1, Cole, Megan1, Molina-Arcas, Miriam1 miriam.molina@crick.ac.uk, Downward, Julian1,3 julian.downward@crick.ac.uk |
| Source: |
Science Advances. 7/22/2022, Vol. 8 Issue 29, p1-19. 19p. |
| Subject Terms: |
*MACROPHAGE colony-stimulating factor, *T cells, *ANTIGEN presenting cells, *LUNG cancer, *GENETIC regulation, *RAS proteins |
| Abstract: |
The article presents a study on a therapeutic KRASG12C (glycine 12 to cysteine) inhibitor that drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. It discusses that the in vivo KRASG12C inhibitor increases the T cell infiltration and activation. It also describes the mechanism of the KRASG12C inhibition reverses immunosuppression in several preclinical lung cancer models with varying levels of immunogenicity. |
| Database: |
Academic Search Complete |
